Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

112.45
+0.21000.19%
Volume:85.96K
Turnover:9.73M
Market Cap:5.53B
PE:-18.76
High:113.91
Open:113.10
Low:112.13
Close:112.24
Loading ...

Axsome Therapeutics Inc: Statistically Significant Reduction in Overall Adhd Disease Severity as Measured by CGI-S Score Compared to Placebo

THOMSON REUTERS
·
25 Mar

Strong Growth and Positive Outlook for Axsome Therapeutics’ Auvelity Drives Buy Rating

TIPRANKS
·
25 Mar

Strong Market Performance and Growth Potential of Auvelity Drives Positive Outlook for Axsome Therapeutics

TIPRANKS
·
24 Mar

HRMY Down 10.8% in Six Months: How Should You Play the Stock?

Zacks
·
20 Mar

Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock rises 5.8% this past week

Simply Wall St.
·
18 Mar

Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?

Zacks
·
14 Mar

Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025?

Insider Monkey
·
14 Mar

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

Zacks
·
06 Mar

TD Cowen Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

TIPRANKS
·
06 Mar

Axsome Therapeutics Price Target Maintained With a $200.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Mar

Axsome Therapeutics: Strategic Developments and Market Exclusivity Drive Buy Rating

TIPRANKS
·
06 Mar

Axsome Therapeutics management to meet with Piper Sandler

TIPRANKS
·
06 Mar

Axsome Therapeutics Resolves Sunosi Patent Case With Hikma

MT Newswires Live
·
05 Mar

Axsome Therapeutics Inc - Hikma to Sell Generic Sunosi From Sept 2040 IF Pediatric Exclusivity Granted

THOMSON REUTERS
·
05 Mar

Axsome Therapeutics Settles Sunosi® (Solriamfetol) Patent Litigation With Hikma Pharmaceuticals USA

THOMSON REUTERS
·
05 Mar

Axsome Therapeutics Inc - Co and Hikma to Submit Settlement Agreement for FTC and DOJ Review

THOMSON REUTERS
·
05 Mar

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

GlobeNewswire
·
05 Mar

Axsome Therapeutics (AXSM) Gets a Buy from Mizuho Securities

TIPRANKS
·
05 Mar

Axsome Therapeutics: Promising Regulatory Progress and Market Potential Justify Buy Rating

TIPRANKS
·
04 Mar

Axsome Therapeutics’ AXS-05: Promising Regulatory Progress and Strategic Positioning for Market Success

TIPRANKS
·
04 Mar